{"news_desk": "Business", "print_page": "3", "section_name": "Business Day", "subsection_name": "International Business", "byline": {"original": "By ANDREW POLLACK", "person": [{"rank": 1, "role": "reported", "firstname": "Andrew", "organization": "", "lastname": "POLLACK"}]}, "abstract": "Food and Drug Admin approves Novartis's new heart failure drug Entresto, which has proved to cut deaths and hospitalization from condition by 20 percent.", "type_of_material": "News", "word_count": "715", "lead_paragraph": "The drug, Entresto, could eventually achieve more than $5 billion in annual sales, said Novartis, which developed it.", "pub_date": "2015-07-08T00:00:00Z", "document_type": "article", "slideshow_credits": null, "headline": {"main": "F.D.A. Approves Heart Drug Entresto Said to Cut Death Risk by 20%", "print_headline": "F.D.A. Approves Drug Said to Cut Death Risk in Heart Patients by 20 Percent"}, "snippet": "The drug, Entresto, could eventually achieve more than $5 billion in annual sales, said Novartis, which developed it.", "multimedia": [], "web_url": "http://www.nytimes.com/2015/07/08/business/international/fda-approves-heart-drug-entresto-after-promising-trial-results.html", "keywords": [{"rank": "1", "is_major": "Y", "value": "Heart", "name": "subject"}, {"rank": "2", "is_major": "Y", "value": "Novartis AG", "name": "organizations"}, {"rank": "3", "is_major": "Y", "value": "Drugs (Pharmaceuticals)", "name": "subject"}, {"rank": "4", "is_major": "Y", "value": "Food and Drug Administration", "name": "organizations"}], "blog": [], "_id": "559c534138f0d81b1af2d48f", "source": "The New York Times"}